JMP Securities Reaffirms “Market Perform” Rating for Vigil Neuroscience (NASDAQ:VIGL)

JMP Securities restated their market perform rating on shares of Vigil Neuroscience (NASDAQ:VIGL) in a report published on Thursday,Benzinga reports.

VIGL has been the subject of several other research reports. Wedbush restated a “neutral” rating and issued a $8.00 target price (down previously from $13.00) on shares of Vigil Neuroscience in a report on Thursday. HC Wainwright lowered their target price on shares of Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating for the company in a report on Friday, March 14th. Guggenheim restated a “buy” rating on shares of Vigil Neuroscience in a report on Friday, January 24th. Finally, William Blair restated a “market perform” rating on shares of Vigil Neuroscience in a report on Thursday. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Vigil Neuroscience currently has a consensus rating of “Hold” and a consensus target price of $15.00.

Vigil Neuroscience Trading Up 241.1%

Shares of Vigil Neuroscience stock opened at $7.88 on Thursday. The company has a fifty day simple moving average of $2.07 and a 200-day simple moving average of $2.27. Vigil Neuroscience has a 12-month low of $1.31 and a 12-month high of $7.95. The stock has a market cap of $367.78 million, a price-to-earnings ratio of -3.83 and a beta of 1.90.

Vigil Neuroscience (NASDAQ:VIGL) last issued its earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.04. On average, analysts forecast that Vigil Neuroscience will post -2.07 earnings per share for the current fiscal year.

Institutional Trading of Vigil Neuroscience

Several institutional investors and hedge funds have recently bought and sold shares of the business. Cubist Systematic Strategies LLC raised its position in Vigil Neuroscience by 53.0% in the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company’s stock valued at $41,000 after purchasing an additional 8,358 shares during the last quarter. Northern Trust Corp raised its position in Vigil Neuroscience by 29.0% in the 4th quarter. Northern Trust Corp now owns 64,737 shares of the company’s stock valued at $110,000 after purchasing an additional 14,572 shares during the last quarter. Barclays PLC raised its position in Vigil Neuroscience by 43.6% in the 4th quarter. Barclays PLC now owns 64,049 shares of the company’s stock valued at $109,000 after purchasing an additional 19,436 shares during the last quarter. Two Sigma Investments LP raised its position in Vigil Neuroscience by 44.0% in the 4th quarter. Two Sigma Investments LP now owns 136,920 shares of the company’s stock valued at $233,000 after purchasing an additional 41,836 shares during the last quarter. Finally, Jane Street Group LLC purchased a new stake in Vigil Neuroscience in the 4th quarter valued at $83,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.